Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC Wainwright

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Friday, March 22nd.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX traded down $0.01 on Tuesday, hitting $1.57. The stock had a trading volume of 100,096 shares, compared to its average volume of 491,367. Compass Therapeutics has a twelve month low of $1.15 and a twelve month high of $3.62. The firm’s 50 day moving average price is $1.84 and its 200-day moving average price is $1.73. The company has a market capitalization of $215.77 million, a price-to-earnings ratio of -4.68 and a beta of 0.78.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). As a group, sell-side analysts predict that Compass Therapeutics will post -0.48 EPS for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. BlackRock Inc. raised its holdings in Compass Therapeutics by 291.5% during the 2nd quarter. BlackRock Inc. now owns 6,032,292 shares of the company’s stock worth $19,183,000 after purchasing an additional 4,491,397 shares during the last quarter. Blue Owl Capital Holdings LP bought a new stake in Compass Therapeutics during the 4th quarter worth about $4,414,000. Braidwell LP raised its holdings in Compass Therapeutics by 79.0% during the 1st quarter. Braidwell LP now owns 3,247,847 shares of the company’s stock worth $10,620,000 after purchasing an additional 1,433,581 shares during the last quarter. State Street Corp raised its holdings in Compass Therapeutics by 334.1% during the 2nd quarter. State Street Corp now owns 1,746,514 shares of the company’s stock worth $5,554,000 after purchasing an additional 1,344,201 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Compass Therapeutics by 104.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,808,207 shares of the company’s stock valued at $5,750,000 after acquiring an additional 924,644 shares during the last quarter. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.